NCT06327256View on ClinicalTrials.gov

A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

September 27, 2024

Study Completion Date

September 27, 2024

Conditions
Healthy
Interventions
DRUG

BI 3000202

BI 3000202

DRUG

Placebo

Placebo-matching BI 3000202

DRUG

Midazolam

Midazolam

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06327256 - A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam | Biotech Hunter | Biotech Hunter